EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Burden of Pancreatic Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction up to 2036: A Systemic Analysis of the Global Burden of Diseases Study 2021

Tianhao Guo iD, Wenjian Zhu iD, Yifan Hui iD, Yuhan Wang, Tingting Zhou iD, Weixing Shen, Liu Li, Yu Yang, Haibo Cheng iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tianhao Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health and Regimen, Jiangsu Open University, Nanjing, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Global Burden of Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine, NATCM's Project of High-level Construction of Key TCM Disciplines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer (PC) presents a significant challenge for prevention and treatment, posing a serious threat to the health and lives of patients. The five East Asian countries (China, Japan, North Korea, South Korea, and Mongolia) represent one of the most significant regions globally in terms of PC burden.

Methods

We retrieved data from the Global Burden of Disease (GBD) Study 2021 regarding the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability‐adjusted life years (DALYs) associated with PC in these five East Asian countries from 1990 to 2021. We employed joinpoint, age‐period‐cohort (APC), and decomposition analysis methods to assess the epidemiological characteristics of PC. To project the future burden of PC through 2036, we applied two prediction models: Autoregressive Integrated Moving Average (ARIMA) and Bayesian age‐period‐cohort (BAPC) models.

Results

China recorded the highest incidence, prevalence, mortality, YLLs, YLDs, and DALYs among the five East Asian countries in both 1990 and 2021. Japan exhibited the highest age‐standardized incidence rate (ASIR), age‐standardized mortality rate (ASMR), age‐standardized prevalence rate (ASPR), and age‐standardized YLDs rate in both 1990 and 2021. Mongolia experienced significant increases in the number and rates of incidence, prevalence, death, YLLs, YLDs, and DALYs from 1990 to 2021. The age group with the highest prevalence, incidence, mortality, YLDs, YLLs, and DALYs rates across the five East Asian countries was consistently those aged 70 and older. The incidence rate across the five countries is influenced by aging populations, surpassing global averages. Projections for 2030 and 2036 suggest that Japan will have the highest ASPR (13.23 in 2030 and 13.85 in 2036), ASIR (12.14 in 2030 and 12.53 in 2036), and ASMR (10.97 in 2030 and 11.39 in 2036) among the countries.

Conclusion

The disease burden of PC in the five East Asian countries has steadily increased over the past three decades, particularly among older adults due to population aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsGlobal Burden of DiseaseHumansIncidencePrevalenceDisability-Adjusted Life YearsMaleMiddle AgedFemaleAgedAsia, EasternAdultJapanAged, 80 and overBayes TheoremCost of IllnessQuality-Adjusted Life YearsEast Asian People

Stichwörter der Autor:innen

Global Burden of Disease Studyage‐period‐cohort analysisdisease burdenepidemiological studyjoinpoint regressionpancreatic cancer

Autor:innen und Institutionen

  • Institute of Health and Regimen, Jiangsu Open University, Nanjing, Jiangsu, People's Republic of China.
  • Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing, Jiangsu, People's Republic of China.
  • The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
  • Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
  • Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.

ORCID-Profile: Tianhao Guo, Wenjian Zhu, Yifan Hui, Tingting Zhou, Haibo Cheng

Förderung

  • National Key Research and Development Program of China
  • Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
  • NATCM's Project of High-level Construction of Key TCM Disciplines
  • Qing Lan Project of Jiangsu Higher Education Institutions
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • General project of Universities' philosophy and social science in Jiangsu Province

Zitieren

APA

Guo, T., Zhu, W., Hui, Y., Wang, Y., Zhou, T., Shen, W., Li, L., Yang, Y., & Cheng, H. (2025). The Burden of Pancreatic Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction up to 2036: A Systemic Analysis of the Global Burden of Diseases Study 2021. Cancer Medicine. https://doi.org/10.1002/cam4.70656

Vancouver

Guo T, Zhu W, Hui Y, Wang Y, Zhou T, Shen W, et al. The Burden of Pancreatic Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction up to 2036: A Systemic Analysis of the Global Burden of Diseases Study 2021. Cancer Medicine. 2025. doi:10.1002/cam4.70656

BibTeX
@article{Guo2025,
  author = {Guo, Tianhao and Zhu, Wenjian and Hui, Yifan and Wang, Yuhan and Zhou, Tingting and Shen, Weixing and Li, Liu and Yang, Yu and Cheng, Haibo},
  title = {The Burden of Pancreatic Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction up to 2036: A Systemic Analysis of the Global Burden of Diseases Study 2021},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70656}
}
Kostenlos starten →